The ACE Inhibitors

The death rate in patients with multiple comorbid conditions of metabolic dysfunction is vastly greater than the general population. Less than 12.2% of the US population does not have severe metabolic inflammation or metabolic dysfunction. Profoundly, the very drug class that is the preferred for blood pressure management in metabolic syndrome, may dramatically increase Coronavirus… Continue reading The ACE Inhibitors